Back to Newsroom

Quark Pharmaceuticals Launches to Promote NAION Study

FREMONT, Calif., Oct. 14, 2016 /PRNewswire/ — Quark Pharmaceuticals, Inc. today announced the launch of to promote public awareness and subject recruitment for a global Phase II/III clinical study evaluating QPI-1007, an investigational drug designed to stop further vision loss in patients with early diagnosis of Non-arteritic Anterior Ischemic Optic Neuropathy, or NAION.

Click here to read the full release